Microbiome-based informed method to formulate live biotherapeutics

A live biotherapeutic formulation adapted for administration to a vaginal environment of a female human subject, comprising a selected strain or consortium of strains, wherein the selected strain or consortium of strains consists essentially of any combination of:

• (i) Lactobacillus crispatus bacteria configured to express at least one of the asparagine synthase B (asnB) gene of SEQ ID NO:
• 2 and the asparagine synthase B (asnB) gene of SEQ ID NO:
• 3;
• and
• (ii) Lactobacillus crispatus bacteria containing an asparagine synthase B (asnB) gene encoding at least one of a polypeptide of SEQ ID NO:
• 5 and a polypeptide of SEQ ID NO:
• 6;
• and
• wherein the live biotherapeutic formulation further comprises at least one of an antimicrobial agent, a redox potential control agent and a pH buffer configured to maintain a healthy pH of the vaginal environment.

A live biotherapeutic formulation adapted for administration to a vaginal environment of a female human subject, comprising bacteria adapted to remedy a deficiency or excess of at least one bacterial strain in the subject's vaginal microbial community, wherein the bacteria comprise a selected strain or consortium of strains comprises at least one of:

• (i) Lactobacillus crispatus bacteria configured to express at least one of the asparagine synthase B (asnB) gene of SEQ ID NO:
• 2 and the asparagine synthase B (asnB) gene of SEQ ID NO:
• 3;
• and
• (ii) Lactobacillus crispatus bacteria containing an asparagine synthase B (asnB) gene encoding at least one of a polypeptide of SEQ ID NO:
• 5 and a polypeptide of SEQ ID NO:
• 6,
• wherein the live biotherapeutic formulation further comprises at least one of an antimicrobial agent and a pH buffer configured to maintain a healthy pH of the vaginal environment.